文献速递睡眠呼吸障碍

睡眠呼吸暂停治疗的成本效益:对治疗影响医疗费用的批判性评估

The Cost-Effectiveness of Sleep Apnea Management: A Critical Evaluation of the Impact of Therapy on Health Care Costs.
PubMed 文献 · Chest · 2024-05-28

本文综述 OSA 管理的成本效益,指出 OSA 治疗可改善症状性中重度患者的生活质量且具成本效益,但治疗能否降低医疗费用仍不确定;随机对照试验未显示 PAP 治疗降低费用但存在局限,观察性研究提示仅高依从者费用增幅可能减缓,健康依从者效应是重要偏倚来源。

要点

  • OSA 治疗改善症状性中重度患者健康相关生活质量,且经济研究显示具高成本效益。
  • PAP 随机对照试验未证实降低医疗费用,但研究存在重要局限。
  • 观察性研究提示仅高依从患者费用增幅可能减缓,健康依从者效应是潜在偏倚。

核心结论

  • OSA 管理具成本效益,但治疗对医疗费用的影响仍存在不确定性。

研究设计与样本

  • 综述类:围绕 OSA 管理的成本效益及治疗对医疗费用影响的文献进行批判性评估。

主要发现

  • OSA 治疗可改善健康相关生活质量,尤其对症状性中重度患者。
  • 未治疗 OSA 与医疗费用增加相关,但治疗能否降低费用不确定。
  • PAP 随机对照试验未显示费用降低,但研究存在重要局限。
  • 观察性研究提示 PAP 治疗可能减缓费用增长,但仅见于高依从患者。
  • 健康依从者效应是观察性研究中的重要潜在偏倚来源。

临床怎么用

  • 评估 OSA 治疗价值时应兼顾生活质量改善与成本效益,不宜仅以降低医疗费用为目标。
  • 解读 PAP 费用相关观察性证据时需考虑健康依从者效应等偏倚。

局限性

  • PAP 随机对照试验存在重要局限,未能证实费用降低。
  • 观察性研究受健康依从者效应等偏倚影响,治疗与费用关系仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC IMPORTANCE: OSA is a widespread condition that significantly affects both health and health-related quality of life (HRQoL). If left untreated, OSA can lead to accidents, decreased productivity, and medical complications, resulting in significant economic burdens including the direct costs of managing the disorder. Given the constraints on health care resources, understanding the cost-effectiveness of OSA management is crucial. A key factor in cost-effectiveness is whether OSA therapies reduce medical costs associated with OSA-related complications. REVIEW FINDINGS: Treatments for OSA have been shown to enhance HRQoL, particularly for symptomatic patients with moderate or severe disease. Economic studies also have demonstrated that these treatments are highly cost-effective. However, although substantial empirical evidence shows that untreated OSA is associated with increased medical costs, uncertainty remains about the impact of OSA treatment on these costs. Randomized controlled trials of positive airway pressure (PAP) therapy have failed to demonstrate cost reductions, but the studies have had important limitations. Observational studies suggest that PAP therapy may temper increases in costs, but only among patients who are highly adherent to treatment. However, the healthy adherer effect is an important potential source of bias in these studies. SUMMARY: OSA management is cost-effective, although uncertainties persist regarding the therapy's impact on medical costs. Future studies should focus on reducing bias, particularly the healthy adherer effect, and addressing other confounding factors to clarify potential medical cost savings. Promising avenues to further understanding include using quasiexperimental designs, incorporating more sophisticated characterization of OSA severity and symptoms, and leveraging newer technologies (eg, big data, wearables, and artificial intelligence).

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Pendharkar SR, Kaambwa B, Kapur VK, et al. The Cost-Effectiveness of Sleep Apnea Management: A Critical Evaluation of the Impact of Therapy on Health Care Costs. Chest. 2024. PMID: 38815624. doi:10.1016/j.chest.2024.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。